Puma Biotechnology, Inc.
Moat Score — Puma Biotechnology, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Patent protection and regulatory exclusivity for NERLYNX across 40+ countries provide real, if contested, IP protection, though ongoing European patent oppositions introduce some risk. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small specialty biopharma relying on sub-license partners internationally, Puma has no structural cost advantage over larger oncology competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Specialty oncology pricing for an approved, differentiated mechanism gives Puma some pricing power, tempered by growing competition from newer HER2-targeted and combination therapies. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effect exists in pharmaceutical commercialization of this kind. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Once oncologists establish a HER2-positive treatment regimen there is some prescribing inertia, but new therapies such as those tested in DESTINY-Breast05 threaten to erode that stickiness. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Puma's single-product commercial scale is modest next to large oncology competitors, and its reliance on sub-licensees abroad reflects a capital-efficient rather than scale-driven model. |